Browsing by Subject "chronic myeloid leukemia"
Now showing items 1-6 of 6
-
Clinical cardiac safety profile of nilotinib
(Ferrata Storti Foundation (Haematologica), 2012-01-22)Background Nilotinib is a second-generation tyrosine kinase inhibitor with significant efficacy as first-or second-line treatment in patients with chronic myeloid leukemia. Despite preclinical evidence indicating a risk ... -
Concurrent use of proton pump inhibitors or h2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia
(Springer Nature, 2012-05-24)The impact of proton pump inhibitors (PPIs) and histamine H2 receptor antagonists (H2 blockers) on the efficacy of nilotinib was evaluated. Retrospective analyses were performed in patients with newly diagnosed Philadelphia ... -
Deregulated expression of the hsp40 family members auxilin-1 and -2 is indicative of proteostasis imbalance and predicts patient outcome in ph+ leukemia
(Springer Nature, 2015-12-01)Background: Proteostasis is defined by the orchestrated control of anabolic and catabolic protein pathways. Disruption of proteostasis results in cell stress and adaptation to proteostasis imbalance is mediated by adaptive ... -
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase
(Springer Nature, 2011-12-13)Nilotinib is a selective inhibitor of BCR-ABL approved for use in newly diagnosed and imatinib-resistant or -intolerant patients with chronic myeloid leukemia (CML) in chronic phase. In this study, 400mg of nilotinib was ... -
Prediction of outcomes in patients with ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance
(Springer Nature, 2012-11-06)The purpose was to assess predictive factors for outcome in patients with chronic myeloid leukemia (CML) in chronic phase (CML-CP) treated with nilotinib after imatinib failure. Imatinib-resistant and -intolerant patients ... -
Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis
(Springer Nature, 2013-03-05)Peripheral arterial occlusive disease (PAOD) occurs in patients with chronic phase chronic myeloid leukemia (CML-CP) treated with tyrosine kinase inhibitors (TKIs). The risk of developing PAOD on TKI therapy is unknown and ...